Dendreon plans to lay off 500 following disappointing Provenge uptake
This article was originally published in Scrip
Dendreon's restructuring in order to trim expenses will hurt. The Seattle-based firm said it would lay off 500 employees, or about one-quarter of its work force, in reaction to sales of its prostate cancer immunotherapy, Provenge (sipuleucel-T), that have fallen short of its ambitious projections. Although the largest proposed job cuts are in manufacturing, the company is still looking for a contract manufacturing partner in Europe as its moves toward filing for approval of the treatment there at the turn of the this year.
You may also be interested in...
Mitchell Gold, who once led Dendreon, will lead the company, which obtains $90m in funding to bring forward three potential drug candidates for inflammatory conditions and cancer.
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.